BioSpace News Archive

These events will be webcast live and a replay will be available on 3M’s Investor Relations website at http://investors.3M.com.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company approved the grant of equity awards to two new employees with a grant date of May 3, 2021, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Albireo Pharma, Inc., a clinical-stage rare liver disease company developing novel bile acid modulators, announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 first quarter financial results on Thursday, May 13, 2021, after the close of the U.S. financial markets.

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its first quarter 2021 financial results on Tuesday, May 11, 2021, before the U.S. financial markets open.

Pamiparib becomes the first PARP inhibitor approved in both platinum-sensitive and platinum-resistant relapsed ovarian cancer in China

Significant advancements in the animal healthcare industry is compelling the market players to invest more in the development of quality breed poultry animals

Rising population of livestock animals and growing adoption of pets are stimulating high demand for ectoparasiticides, boosting the animal parasiticides sales

Botulinum toxin, known to the mankind as one of the most poisonous biological substances, is a neurotoxin produced by the Clostridium botulinum bacteria.

Adoption of cashless payment platforms such as Android Pay and Apple Pay is revolutionizing the health kiosk market in an era where using credit and debit cards is the widely accepted culture.